Red ink continues to flow at MBI

Article

Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high

Ultrasound contrast agent developer Molecular Biosystems remains beset by heavy losses, despite signs of increasing market interest in its Optison ultrasound contrast agent. MBI, which announced a restructuring plan in November to reduce its high cash-burn rate (SCAN 11/25/98), reported a net loss of $11.9 million during its fiscal third quarter (end-December), compared with a net loss of $5.9 million in the same period in 1997. Revenues were $2.2 million, compared with $1.4 million last year. Optison sales totaled $509,000 during the quarter.

The news wasn't all negative, however. The San Diego firm reported a 37% increase in end-user demand for Optison, representing the fourth straight quarter of growing acceptance and demand for the agent, according to MBI. This increased demand has not benefited the firm's financial results, as inventories already sold to the distribution channel were sufficient to meet the demand, according to the firm. If these sales rates continue to hold up, the company expects to have the initial inventories of Optison shipped by the quarter ending in June.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.